Previous 10 | Next 10 |
CAMBRIDGE, Mass. , Feb. 4, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi , Chief Financial Officer, will present a corporate overview at...
Investors often wonder if it is possible to make money with penny stocks . People who start out with small capital think about investing in these stocks. Although there are risks involved, the profits can sometimes be enormous. This is why we sometimes see many younger investors turning to pen...
Co-Diagnostics (NASDAQ: CODX ) +158% readies coronavirus test . More news on: Co-Diagnostics, Inc., Trans World Entertainment Corporation, MarineMax, Inc., Stocks on the move, , Read more ...
Updated results from a recently completed Phase 1/2 clinical trial, P102 (KEYNOTE-731), evaluating Leap Therapeutics' (NASDAQ: LPTX ) DKN-01, combined with paclitaxel or Merck's (NYSE: MRK ) Keytruda (pembrolizumab), in patients with relapsed/refractory esophagogastric cancer showed a p...
CAMBRIDGE, Mass. , Jan. 23, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX) today presented updated clinical data from its recently completed Phase 1/2 clinical trial of DKN-01 in patients with advanced or recurrent esophagogastric cancer (EGC) at the 2020 ASCO GI annual ...
CAMBRIDGE, Mass. , Jan. 7, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of its previously announced equity financing to issue 1,421,801 shares of ne...
Cal-Maine Foods (NASDAQ: CALM ) -9% on Q2 earnings . More news on: Cal-Maine Foods, Inc., Leap Therapeutics, Inc., Trillium Therapeutics Inc., Stocks on the move, Read more ...
Deals and Financings I-Mab, a Phase III Shanghai immunoncology-autoimmune biopharma, announced the terms for its $100 million IPO on the NASDAQ exchange at a market value of $750 million (see story ). The company plans to offer 7.4 million shares at a price that ranges from $12 to $15. Fina...
Losers: Leap Therapeutics (NASDAQ: LPTX ) +49% . More news on: Leap Therapeutics, Inc., Yuma Energy, Inc., Inpixon, Stocks on the move, Read more ...
Leap Therapeutics (NASDAQ: LPTX ) is up 38% premarket on announcing an exclusive option and license agreement with BeiGene (NASDAQ: BGNE ) for the clinical development and commercialization of DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in Asia (excluding Japan), Austr...
News, Short Squeeze, Breakout and More Instantly...
Leap Therapeutics Inc. Company Name:
LPTX Stock Symbol:
NASDAQ Market:
Leap Therapeutics Inc. Website:
Leap Therapeutics Reports First Quarter 2024 Financial Results PR Newswire CAMBRIDGE, Mass. , May 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today report...
Leap Therapeutics Announces $40 Million Private Placement PR Newswire Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and development prog...
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire CAMBRIDGE, Mass. , March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeut...